|1.||Votrubova, Jana: 1 article (06/2014)|
|2.||Vojackova, Nadezda: 1 article (06/2014)|
|3.||Juzlova, Katerina: 1 article (06/2014)|
|4.||Fialova, Jorga: 1 article (06/2014)|
|5.||Gopfertova, Dana: 1 article (06/2014)|
|6.||Hercogova, Jana: 1 article (06/2014)|
|7.||Smerhovsky, Zdenek: 1 article (06/2014)|
|8.||Pérez-Pérez, María-Jesús: 1 article (05/2006)|
|9.||Balzarini, Jan: 1 article (05/2006)|
|10.||Hernández, Ana-Isabel: 1 article (05/2006)|
08/01/1977 - "Ara-T also selectively inhibited the replication of equine herpesvirus type 1 (EHV-1) in vitro and was effective against EHV-1 infection in vivo in hamsters. "
01/01/1984 - "This is the first report of the in vivo efficacy of Ara-T for HSV-1 skin infections."
01/01/1984 - "HSV-2 infection was refractory to both topical and iontophoretic application of Ara-T. "
01/01/1984 - "Anodal (+) iontophoresis of 0.4% Ara-T in a 0.1 M NaCl solution significantly suppressed HSV-1 skin infection, but the infection was not altered by topical application of 3% Ara-T. "
01/01/1984 - "The antiviral agent thymine arabinoside (9-beta-D-arabinofuranosyl thymine, Ara-T) was applied topically and by anodal (+) iontophoresis in a NaCl solution to Herpes simplex virus type 1 (HSV-1), and Herpes simplex virus type 2 (HSV-2) skin infections in hairless mice. "
|2.||Encephalitis (Encephalitis, Rasmussen)
02/01/1980 - "1-beta-D-Arabinofuranosylthymine (ara-T) was examined for its therapeutic efficacy against encephalitis in mice inoculated intracerebrally with herpes simplex virus. "
09/01/1982 - "When tested against experimental encephalitis in mice inoculated intracerebrally with HSV-1, intraperitoneal or intravenous treatment with 150 mg/kg/day of ara-TMP or 100 mg/kg/day of ara-T, for 5 days was effective in increasing in the mean survival time of mice. "
09/01/1981 - "The results indicate that 1% Ac2IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not."
09/01/1981 - "Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis."
08/01/1979 - "The araU derivatives tested were as active against HSV WT-34, an isolate from a patient with keratitis, as against HSV type 1. Against an IUdR-resistant isolate, HSV WT-20, arabinosylthymine was less inhibitory than IUdR. "
09/01/1981 - "The therapeutic efficacy of three new antiviral agents-5-iodo-3',5'-diacetyl-2'-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside-is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. "
|2.||Antiviral Agents (Antivirals)
|5.||Antineutrophil Cytoplasmic Antibodies (ANCA)